Liver cancer rarely causes symptoms in its early stages, which makes proactive screening the only reliable way to catch it before it spreads. The difference is stark: the five-year survival rate for liver cancer found while still confined to the liver is 37%, compared to just 3% when it has reached distant organs like the lungs or bones. Early detection depends almost entirely on regular surveillance if you’re at higher risk, since waiting for symptoms means the cancer has likely already grown significantly.
Why Symptoms Won’t Help You Catch It Early
The CDC states plainly that early-stage liver cancer “may not have symptoms that can be seen or felt.” The liver is a large organ with significant functional reserve, meaning a tumor can grow for months before it disrupts anything you’d notice. By the time symptoms appear, the cancer is often advanced.
The symptoms that do eventually show up include discomfort in the upper right abdomen, a hard lump just below the rib cage on the right side, unexplained weight loss, loss of appetite, unusual tiredness, jaundice (yellowing of the skin and eyes), easy bruising or bleeding, nausea, and pain near the right shoulder blade. These overlap with many other liver conditions, which makes them unreliable for distinguishing cancer from other problems. If you’re experiencing several of these, it’s worth getting checked, but the goal is to find cancer before any of them appear.
Who Needs Regular Screening
Liver cancer screening isn’t recommended for the general population. It’s targeted at people whose liver is already under stress from chronic disease. The major risk factors include chronic hepatitis B infection, chronic hepatitis C infection, cirrhosis from any cause (alcohol use, fatty liver disease, autoimmune conditions), and certain inherited liver disorders. People with cirrhosis carry the highest risk regardless of what caused it.
Fatty liver disease tied to metabolic problems (obesity, diabetes, high triglycerides) is becoming one of the fastest-growing risk factors. If you have significant liver scarring from fatty liver disease, you fall into the surveillance category even without a viral hepatitis diagnosis. A liver stiffness test, which uses a specialized ultrasound called elastography, can help determine where you stand. A normal liver measures below 6 kilopascals (kPa). Patients with cirrhosis typically measure between 12.5 and 75.5 kPa. In a study of more than 1,800 veterans with hepatitis C and cirrhosis, cancer risk climbed 3% for every one-point increase in stiffness. Patients with stiffness below 10 kPa had a 2% annual cancer risk, while those above 25 kPa had a 5.4% annual risk. If your stiffness is below 5 kPa and you don’t have diabetes, the annual risk is low.
The Standard Screening Protocol
The American Association for the Study of Liver Diseases recommends an abdominal ultrasound every six months for people at high risk. This can be combined with a blood test measuring alpha-fetoprotein (AFP), a protein that liver tumors sometimes release at elevated levels. The optimal screening interval falls between four and eight months, with six months being the standard target.
Ultrasound is the backbone of surveillance because it’s noninvasive, widely available, and doesn’t involve radiation. It can detect new masses or nodules in the liver that weren’t there at the last check. However, it has limitations. In people with obesity or a very fatty liver, ultrasound images can be harder to interpret, potentially missing small tumors.
The AFP blood test, used alone, is not very sensitive. Studies show it catches only 39% to 64% of early-stage liver cancers, with specificity ranging from 76% to 97%. That means it misses a substantial number of cancers and occasionally flags false alarms. This is why guidelines recommend it alongside ultrasound rather than as a standalone test. If your AFP is normal, that doesn’t guarantee your liver is cancer-free.
What Happens When Screening Finds Something
If an ultrasound reveals a suspicious nodule, the next step is usually a contrast-enhanced CT scan or MRI. These imaging studies use a special dye injected into a vein to observe how blood flows through the nodule. Liver cancers have a characteristic pattern: they light up brightly when arterial blood rushes in, then fade (or “wash out”) as the dye moves into later phases. This pattern is so distinctive that many liver cancers can be diagnosed by imaging alone, without a biopsy.
Radiologists use a standardized scoring system called LI-RADS to categorize what they see. The scale runs from 1 (definitely benign) to 5 (diagnostic of liver cancer), with a category for other types of malignancy as well. A nodule rated LI-RADS 3 sits in a gray zone and usually requires follow-up imaging in a few months. LI-RADS 4 means the nodule is probably cancerous but doesn’t yet meet full diagnostic criteria. LI-RADS 5 is reserved for masses that show the hallmark blood flow pattern along with features like rapid growth, defined as a diameter increase greater than 50% within six months or doubling within a year.
Biopsy is reserved for cases where imaging is inconclusive. For nodules that clearly meet LI-RADS 5 criteria, treatment planning can begin without one.
Blood-Based Tests on the Horizon
A newer approach called liquid biopsy analyzes fragments of DNA shed by tumors into the bloodstream. One test, called DELFI, uses machine learning to detect patterns in these DNA fragments that distinguish people with liver cancer from those without it. In a study of 501 people across the U.S. and Europe, DELFI scored 0.9 on a 0-to-1 performance scale when separating liver cancer patients from people with liver disease alone. For distinguishing cancer patients from healthy individuals, it scored 0.98.
The comparison with AFP was striking. AFP correctly identified 52% of people with liver cancer in the study group. DELFI caught 85%, including a higher percentage of those with early-stage disease. In a separate validation group of 223 people in Hong Kong, mostly with hepatitis B or cirrhosis, DELFI again performed well, scoring 0.97 at distinguishing cancer from liver disease. These tests are not yet part of routine clinical practice, but they represent a significant potential improvement over current blood-based screening.
Reducing Your Risk Before Cancer Develops
For people with chronic hepatitis B, antiviral treatment does more than control the virus. It substantially lowers the chance of developing liver cancer. In one study of hepatitis B patients without cirrhosis, antiviral therapy reduced liver cancer risk by roughly 76% compared to untreated patients. Treating hepatitis C with modern antiviral medications similarly reduces long-term cancer risk, though the benefit is greatest when treatment happens before cirrhosis sets in.
Beyond antiviral therapy, managing the underlying liver disease is the most effective prevention. For fatty liver disease, that means weight loss, blood sugar control, and reducing alcohol intake. Losing even 5% to 10% of body weight can meaningfully reduce liver fat and inflammation. For alcohol-related liver disease, stopping drinking slows further scarring and lowers cancer risk over time.
If you already have cirrhosis, the damage that elevates cancer risk is largely done, which is exactly why consistent screening every six months matters so much. The goal shifts from preventing cancer to finding it at a stage where treatment, including surgical removal or liver transplant, can still offer a meaningful chance of long-term survival.